Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
At a Duopharma-sponsored symposium during the Diabetes Asia Conference 2019 at Hotel Istana, Kuala Lumpur, Professor Dato’ Dr Mafauzy Mohamed spoke about the role of biosimilar insulin glargine in improving access to diabetes treatment, presenting important evidence that affirms the quality, efficacy and safety of the biosimilar product.
The latest research, clinical data and innovations in
ophthalmology were presented at the 2019 Annual Meeting of the American Academy
of Ophthalmology (AAO) in San Francisco, USA, held on 12−15 October 2019. As in
previous years, an international panel of renowned ophthalmologists attended
the meeting and contributed articles to Eye on AAO 2019 – an e-Bulletin series featuring
research highlights and hot topics presented at the meeting, with commentaries
on their relevance to clinical practice in the Asia Pacific and Latin American regions.
At a recent Boehringer Ingelheim-sponsored symposium held in conjunction with the 10th Malaysian Endocrine and Metabolic Society Annual Congress, two distinguished speakers spoke on the latest updates in glucose-lowering therapy for the treatment for type 2 diabetes mellitus (T2DM) and highlighted some important cardiovascular outcome trial results of these antidiabetic agents.
At the recent Takeda Malaysia Vocinti® (vonoprazan) launch, held in conjunction with the Annual Scientific Meeting of the Malaysian Society of Gastroenterology and Hepatology - GUT 2019 at Shangri-La Kuala Lumpur, Professor Akihito spoke about vonoprazan’s merits as an alternative to conventional proton pump inhibitors.
The incidence of prostate cancer (PC) and cardiovascular disease (CVD) typically increases with age; therefore, the choice of treatment for PC should take into account a patient’s underlying cardiovascular conditions. In this interview, Professor Laurence Klotz shared his take on androgen deprivation therapy (ADT) options for patients with prostate cancer who are at-risk of CV events.
Pertussis is a highly contagious respiratory illness caused by Bordetella pertussis. Despite the introduction of effective infant immunisation programmes and high vaccination coverage, pertussis remains a public health concern.1 Recently, MIMS Doctor spoke to Dato’ Dr Musa Mohd Nordin who gave us some insights into the resurgence of pertussis in Malaysia, highlighting strategies to further strengthen the current vaccine coverage rate (VCR).
Patients undergoing chemotherapy for breast or haematological cancers could potentially reduce their risk of chemotherapy-related cardiotoxicity with the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), or beta-blockers as primary prevention, according to a systematic review and meta-analysis presented at the recent EuroEcho 2019 conference.
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).